Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.62 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5183224 | 1.00 | ANPEP (0.62) | ANPEPENPEPTAAR1SLC6A2SLC6A3 | |
| SCHEMBL2439514 | 1.00 | ANPEP (0.62) | ANPEPENPEPTAAR1SLC6A2SLC6A3 | |
| Amphetamine SCHEMBL29185448 | 0.89 | TAAR1 (0.70) | ANPEPENPEPTAAR1SLC6A2SLC6A3 | |
| Amphetamine SCHEMBL21464672 | 0.89 | TAAR1 (0.70) | ANPEPENPEPTAAR1SLC6A2SLC6A3 | |
| SCHEMBL6539936 | 0.88 | ANPEP (0.51) | ANPEPENPEPTAAR1SLC6A2SLC6A3 | |
| SCHEMBL9392575 | 0.84 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL6764390 | 0.84 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL8136474 | 0.84 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL8745472 | 0.84 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL1048952 | 0.84 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118028200-A | Acetobacter xylosojae gene engineering bacterium with bcsC knocked out gene, construction method and application thereof | 华东师范大学 | 2024-05-14 | — | — | CN | claimed |
| CN-116949082-A | Reverse screening method of zymomonas mobilis based on pheS gene and application thereof | 武汉轻工大学 | 2023-10-27 | — | — | CN | claimed |
| CN-113660957-A | Compositions, methods, and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2021-11-16 | — | — | CN | claimed |
| CN-110959041-A | Methods and compositions for enhancing the production of proteins containing unnatural amino acids | AMBRX公司 | 2020-04-03 | — | — | CN | claimed |
| WO-2016207626-A1 | FLUOROGENIC COMPOUNDS, PROCESS OF PREPARATION THEREOF AND METHODS OF USE | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-12-29 | — | — | WO | claimed |
| CN-104961756-A | Preparation method of (S)-Boc-4-dihydroxyborylphenylalanine | SHANGHAI INST TECHNOLOGY | 2015-10-07 | — | — | CN | claimed |
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | claimed |
| US-20030082575-A1 | Translation system for use in the generation of protein containing adjusted amino acid sequences | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-05-01 | — | — | US | claimed |
| EP-0656904-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR INC. (US) | 1995-06-14 | — | — | EP | claimed |
| EP-0584244-A1 | PEPTIDE INHIBITORS OF INFLAMMATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1993024526-A1 | PEPTIDE INHIBITORS OF SELECTIN BINDING | CENTOCOR, INC. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1992020708-A1 | PEPTIDE INHIBITORS OF INFLAMMATION | BOARD OF REGENTS FOR THE UNIVERSITY OF OKLAHOMA (US) | 1992-11-26 | — | — | WO | claimed |
| EP-4724152-A1 | ANTIPERSPIRANT COMPOSITION | Unilever IP Holdings B.V. (NL) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025132032-A1 | PERSONAL CARE COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-06-26 | — | — | WO | disclosed |
| EP-4536173-A1 | ANTIPERSPIRANT COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-04-16 | — | — | EP | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966764-A | ELECTRON SPIN RESONANCE | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | ANPEP 1351/4885ENPEP 382/4885TAAR1 4608/4885 |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | ANPEP 15/4885ENPEP 55/4885TAAR1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.